Overall, the promising results encouraged us to carry out larger, randomized controlled trials in the future and focus on the immunogenic characteristics of FAP-positive CAFs and the mechanisms of fibroblast-immune crosstalk with immunotherapeutic potential in NSCLC. Here, FAP is linked to non-small cell lung carcinoma.